Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.
D. Gajria
No relevant relationships to disclose
T. A. King
No relevant relationships to disclose
H. Pannu
No relevant relationships to disclose
R. Sakr
No relevant relationships to disclose
A. D. Seidman
No relevant relationships to disclose
A. Syldor
No relevant relationships to disclose
S. Patil
No relevant relationships to disclose
M. Maybody
No relevant relationships to disclose
L. Norton
No relevant relationships to disclose
N. Rosen
No relevant relationships to disclose
C. Hudis
No relevant relationships to disclose
S. Chandarlapaty
Research Funding - Pfizer